Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

International News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Mad Cow disease: Filtration technology in development by Pall Corp. reduces infectious vCJD (variant Creutzfeldt-Jakob disease, the human variant of bovine spongiform encephalopathy) prions in blood below the detection limit of current methods, company announces March 18. Pall will submit a regulatory application in Europe by year-end for its vCJD infectivity assay. Separately, the European Commission endorses InPro's automated conformation-dependent immunoassay (aCDI) and the Prionics-Check luminescence immunoassay (LIA) for BSE March 14. Manufactured by Pierce Biotechnology, the LIA is slated for EU launch in the second quarter...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT018087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel